Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912372112> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2912372112 abstract "Despite the sustained clinical benefit demonstrated by immune checkpoint inhibitors, a majority of patients derive minimal or no appreciable benefit, indicating the urgent need to incorporate novel immunomodulatory targets and therapeutic strategies. Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) catalyze the first and rate-limiting step in the immunosuppressive tryptophan/kynurenine pathway and are both upregulated in a number of tumor types. Although small-molecule IDO1 inhibitors are being clinically evaluated in several tumor types, so far they have not demonstrated significant clinical benefits either as a single agent or in combination with immune checkpoint inhibition. We are developing pegylated kynureninase (Kynase), a kynurenine degrading enzyme, to treat a broader population with IDO1 and/or TDO2 expressing tumors. We believe that a more robust antitumor immune response can be achieved by depleting kynurenine, produced by both IDO1 and TDO2, with Kynase, than by inhibiting only IDO1. The human Kynase (HsKYN) has been successfully engineered to exhibit vastly improved catalytic activity and stability toward kynurenine over the wild-type human enzyme. HsKYN achieved durable and near complete plasma kynurenine depletion in mice, rats and non-human primates. HsKYN demonstrated single agent efficacy in CT26, MC38 and B16-IDO syngeneic mouse models. Tumor gene expression analysis using NanoString revealed that HsKYN treatment upregulated T-cell and NK cell activation signature. More importantly, HsKYN significantly increased the tumor-infiltrating CD8 T-cells and their activation/polyfunctionality, and reduced the Treg population. As a direct comparison, the lead IDO1 inhibitor epacadostat did not impose any meaningful effects on the same immune cell populations. Furthermore, HsKYN showed beneficial combination efficacy with anti-PD-1 that was superior to combined Epacadostat / anti-PD-1. Evidence to date suggest that HsKYN is well tolerated in multiple species. Therefore, immunoprofiling, efficacy and safety results strongly support that Kynase is a more effective therapeutic approach than IDO1 inhibition. HsKYN is moving toward clinical development for treatment of cancers where IDO1 and/or TDO2 pathways play a significant immunosuppressive role. Citation Format: Silvia Coma, Jillian Cavanaugh, James Nolan, Jeremy Tchaicha, Karen McGovern, Everett Stone, John Blazeck, Candice Lamb, George Georgiou, Mark G Manfredi, Michelle Zhang. Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B008." @default.
- W2912372112 created "2019-02-21" @default.
- W2912372112 creator A5009817418 @default.
- W2912372112 creator A5016038898 @default.
- W2912372112 creator A5019513136 @default.
- W2912372112 creator A5028913983 @default.
- W2912372112 creator A5034297559 @default.
- W2912372112 creator A5047788420 @default.
- W2912372112 creator A5052177571 @default.
- W2912372112 creator A5059141420 @default.
- W2912372112 creator A5070873806 @default.
- W2912372112 creator A5076790826 @default.
- W2912372112 creator A5085672356 @default.
- W2912372112 date "2019-02-01" @default.
- W2912372112 modified "2023-10-14" @default.
- W2912372112 title "Abstract B008: Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition" @default.
- W2912372112 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b008" @default.
- W2912372112 hasPublicationYear "2019" @default.
- W2912372112 type Work @default.
- W2912372112 sameAs 2912372112 @default.
- W2912372112 citedByCount "0" @default.
- W2912372112 crossrefType "proceedings-article" @default.
- W2912372112 hasAuthorship W2912372112A5009817418 @default.
- W2912372112 hasAuthorship W2912372112A5016038898 @default.
- W2912372112 hasAuthorship W2912372112A5019513136 @default.
- W2912372112 hasAuthorship W2912372112A5028913983 @default.
- W2912372112 hasAuthorship W2912372112A5034297559 @default.
- W2912372112 hasAuthorship W2912372112A5047788420 @default.
- W2912372112 hasAuthorship W2912372112A5052177571 @default.
- W2912372112 hasAuthorship W2912372112A5059141420 @default.
- W2912372112 hasAuthorship W2912372112A5070873806 @default.
- W2912372112 hasAuthorship W2912372112A5076790826 @default.
- W2912372112 hasAuthorship W2912372112A5085672356 @default.
- W2912372112 hasConcept C104317684 @default.
- W2912372112 hasConcept C127561419 @default.
- W2912372112 hasConcept C185592680 @default.
- W2912372112 hasConcept C203014093 @default.
- W2912372112 hasConcept C2776706248 @default.
- W2912372112 hasConcept C2776710720 @default.
- W2912372112 hasConcept C2777503454 @default.
- W2912372112 hasConcept C2777701055 @default.
- W2912372112 hasConcept C2780674031 @default.
- W2912372112 hasConcept C2908647359 @default.
- W2912372112 hasConcept C502942594 @default.
- W2912372112 hasConcept C515207424 @default.
- W2912372112 hasConcept C55493867 @default.
- W2912372112 hasConcept C71924100 @default.
- W2912372112 hasConcept C83478079 @default.
- W2912372112 hasConcept C86803240 @default.
- W2912372112 hasConcept C8891405 @default.
- W2912372112 hasConcept C98274493 @default.
- W2912372112 hasConcept C99454951 @default.
- W2912372112 hasConceptScore W2912372112C104317684 @default.
- W2912372112 hasConceptScore W2912372112C127561419 @default.
- W2912372112 hasConceptScore W2912372112C185592680 @default.
- W2912372112 hasConceptScore W2912372112C203014093 @default.
- W2912372112 hasConceptScore W2912372112C2776706248 @default.
- W2912372112 hasConceptScore W2912372112C2776710720 @default.
- W2912372112 hasConceptScore W2912372112C2777503454 @default.
- W2912372112 hasConceptScore W2912372112C2777701055 @default.
- W2912372112 hasConceptScore W2912372112C2780674031 @default.
- W2912372112 hasConceptScore W2912372112C2908647359 @default.
- W2912372112 hasConceptScore W2912372112C502942594 @default.
- W2912372112 hasConceptScore W2912372112C515207424 @default.
- W2912372112 hasConceptScore W2912372112C55493867 @default.
- W2912372112 hasConceptScore W2912372112C71924100 @default.
- W2912372112 hasConceptScore W2912372112C83478079 @default.
- W2912372112 hasConceptScore W2912372112C86803240 @default.
- W2912372112 hasConceptScore W2912372112C8891405 @default.
- W2912372112 hasConceptScore W2912372112C98274493 @default.
- W2912372112 hasConceptScore W2912372112C99454951 @default.
- W2912372112 hasLocation W29123721121 @default.
- W2912372112 hasOpenAccess W2912372112 @default.
- W2912372112 hasPrimaryLocation W29123721121 @default.
- W2912372112 hasRelatedWork W11882389 @default.
- W2912372112 hasRelatedWork W1269684 @default.
- W2912372112 hasRelatedWork W13753769 @default.
- W2912372112 hasRelatedWork W17404775 @default.
- W2912372112 hasRelatedWork W18801721 @default.
- W2912372112 hasRelatedWork W19172956 @default.
- W2912372112 hasRelatedWork W2151330 @default.
- W2912372112 hasRelatedWork W6417289 @default.
- W2912372112 hasRelatedWork W6473434 @default.
- W2912372112 hasRelatedWork W8661922 @default.
- W2912372112 isParatext "false" @default.
- W2912372112 isRetracted "false" @default.
- W2912372112 magId "2912372112" @default.
- W2912372112 workType "article" @default.